GEN制药公司报告SUL-238, 一种有前途的阿尔茨海默氏病和帕金森氏病的药物, GEN Pharmaceuticals reports SUL-238, a promising Alzheimer’s and Parkinson’s drug, showed safety and brain delivery in early trial.

GEN制药公司报告说,SUL-238试验阶段1取得了积极成果。 SUL-238是针对老年痴呆症和帕金森病的Mitochondria的口服药物。 GEN Pharmaceuticals reported positive Phase 1 trial results for SUL-238, an oral drug targeting mitochondria for Alzheimer’s and Parkinson’s diseases. 在健康的老年志愿者中,该药物在14天的每天4000毫克或4,500毫克的剂量下是安全的,并且使用得很好,没有严重的副作用或生命迹象或实验室结果的重大变化。 In healthy elderly volunteers, the drug was safe and well-tolerated at doses of 4,000 mg or 4,500 mg daily for 14 days, with no serious side effects or significant changes in vital signs or lab results. 它显示出快速吸收、稳定的血液水平和对脑脊髓液的高渗透度,表明大脑有效输送。 It showed rapid absorption, stable blood levels, and high penetration into cerebrospinal fluid, indicating effective brain delivery. 该化合物激活米托昆德里综合体I和IV,以提升蜂窝能量,支持其进入后期试验阶段。 The compound activates mitochondrial complexes I and IV to boost cellular energy, supporting its advancement into later-stage trials. 在2025年12月2日第18次阿尔茨海默氏病临床试验会议上介绍了结果。 Results were presented at the 18th Clinical Trials on Alzheimer’s Disease conference on December 2, 2025.